A groundbreaking antitrust lawsuit is ensnaring the generic drug industry image

Vox, December 10, 2018
By Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article:

"The exact damages are difficult to know but likely total in the billions of dollars if the allegations are true. These artificially high prices led to health plans and government programs paying more money. Patients who don’t have insurance or whose coverage requires them to pay a lot of money out of their own pocket were also stuck with the bill.

'If proven, these allegations are hugely significant and could give rise to large damage awards,' says Rachel Sachs, a law professor at Washington University in St. Louis."

Read more here!

pharmaceuticals rachel sachs regulation